| First Author | Rünkorg K | Year | 2012 |
| Journal | Behav Brain Res | Volume | 226 |
| Issue | 1 | Pages | 335-9 |
| PubMed ID | 21925544 | Mgi Jnum | J:177730 |
| Mgi Id | MGI:5295906 | Doi | 10.1016/j.bbr.2011.09.005 |
| Citation | Runkorg K, et al. (2012) Rimonabant attenuates amphetamine sensitisation in a CCK2 receptor-dependent manner. Behav Brain Res 226(1):335-9 |
| abstractText | In this behavioural and pharmacological study in male CCK2 receptor-deficient mice (CCK2(-/-)), we evaluated the role of the interaction of endocannabinoids (eCBs) and cholecystokinin (CCK) on the regulation of anxiety-related and motor behaviours. Repeated treatment with amphetamine (2mg/kg daily for four days) induced slightly weaker motor sensitisation in CCK2(-/-) mice compared to their wild-type (CCK2(+/+)) littermates. Co-administration of rimonabant (1mg/kg) with amphetamine antagonised the development of motor sensitisation in CCK2(+/+) mice. However, we did not find a similar effect of rimonabant in CCK2(-/-) mice. We did not find any differences between the behaviour of CCK2(+/+) and CCK2(-/-) mice in models designed to assess emotional behaviours (dark/light exploration, marble burying and conditioned place aversion). This study supports the hypothesis that eCBs play a role in the development of amphetamine-induced sensitisation. Moreover, we have demonstrated that intact CCK2 receptors are necessary for the development of eCB-mediated sensitisation to amphetamine. |
